CS
CSLLY.US CSL Ltd
- Market cap
- USD 66.0B
- P/E
- -
- P/B
- 4.49x
- ROE
- -17.5%
- Dividend yield
- 2.05%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CSLLY.US undervalued?
Graham numberThe Graham number of CSL Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CSL Ltd fundamental analysis
No fundamental analysis for CSL Ltd yet.
CSL Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, mar…
Full company profileCSL Ltd financial statements
CSL Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.06B | 5.59B | 8.54B | 9.10B | 10.3B | 10.5B | 13.2B | 14.8B | 15.4B | 15.8B |
| Gross Profit | 2.52B | 2.99B | 4.78B | 3.59B | 5.74B | 5.66B | 6.71B | 7.56B | 7.95B | 7.52B |
| Operating Income | 1.77B | 1.76B | 2.10B | 1.89B | 2.59B | 2.92B | 2.90B | 3.81B | 2.96B | 4.03B |
| EBITDA | 2.06B | 2.69B | 2.88B | 3.14B | 3.63B | 3.46B | 3.90B | 4.74B | 5.13B | 5.07B |
| Net Income | 1.02B | 1.27B | 1.92B | 1.46B | 1.78B | 2.25B | 2.19B | 2.64B | 3.00B | -2.59B |
| EPS | 0.28 | 0.35 | 0.53 | 0.40 | 0.49 | 0.60 | 0.57 | 0.68 | 0.77 | -1.34 |
| Balance Sheet | ||||||||||
| Total Assets | 6.98B | 7.93B | 8.61B | 10.7B | 13.6B | 28.3B | 36.2B | 38.0B | 39.4B | 33.6B |
| Total Liabilities | 4.56B | 4.93B | 4.94B | 6.19B | 7.34B | 13.8B | 18.4B | 18.6B | 18.0B | 17.3B |
| Shareholders' Equity | 2.42B | 3.00B | 3.67B | 4.52B | 6.29B | 14.6B | 15.8B | 17.4B | 19.3B | 14.8B |
| Cash & Short-term Investments | 646M | 600M | 460M | 828M | 1.36B | 10.4B | 1.55B | 1.66B | 2.16B | 1.51B |
| Total Debt | 3.04B | 3.23B | 3.26B | 4.15B | 4.36B | 9.66B | 12.2B | 12.2B | 11.5B | 10.9B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.24B | 1.40B | 1.64B | 3.61B | 4.83B | 3.81B | 3.91B | 2.76B | 3.56B | 3.53B |
| Capital Expenditure | 659M | 731M | 1.12B | 1.37B | 1.67B | 1.25B | 1.69B | 1.26B | 1.02B | 649M |
| Free Cash Flow | 582M | 669M | 527M | 2.24B | 3.16B | 2.56B | 2.21B | 1.51B | 2.54B | 2.88B |
| Ratios | ||||||||||
| ROE | 42.3% | 42.4% | 52.3% | 32.2% | 28.3% | 15.5% | 13.9% | 15.2% | 15.5% | -17.5% |
| ROA | 14.7% | 16.0% | 22.3% | 13.6% | 13.1% | 8.0% | 6.1% | 6.9% | 7.6% | -7.7% |
| Net Profit Margin | 20.2% | 22.8% | 22.5% | 16.0% | 17.4% | 21.5% | 16.7% | 17.9% | 19.5% | -16.4% |
| Debt to Equity | 1.26x | 1.08x | 0.89x | 0.92x | 0.69x | 0.66x | 0.77x | 0.70x | 0.59x | 0.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CSL Ltd dividends
- Dividend yield
- 2.05%
- Forward dividend
- 0.71 USD
- Payout ratio
- -
- Ex-dividend date
- Sep 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 1.42B | 0.74 | - |
| 2025 | AUD 1.43B | 0.37 | 47.8% |
| 2024 | AUD 1.21B | 0.31 | 45.9% |
| 2023 | AUD 1.24B | 0.32 | 56.5% |
| 2022 | AUD 1.04B | 0.28 | 46.1% |
| 2021 | AUD 958M | 0.26 | 53.7% |
| 2020 | AUD 883M | 0.24 | 60.6% |
| 2019 | AUD 807M | 0.22 | 42.0% |
| 2018 | AUD 495M | 0.14 | 38.9% |
| 2017 | AUD 460M | 0.13 | 45.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 2, 2026.
Who owns CSL Ltd
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 1.92B
- Free float 1.91B
CSL Ltd company profile
- Company name
- CSL Ltd
- Ticker
- CSLLY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29,000
- Fiscal year end
- June
- Address
- 655 Elizabeth Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9389 1911
- Website
- csl.com
About CSL Ltd
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
CSL Ltd management
10- Mr. Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.CEO, MD & Executive Director · born 1963
- Mr. Ken LimChief Financial Officer · born 1974
- Dr. Mary Oates Ph.D.Executive VP & COO · born 1963
- Michelle ReesHead of Investor Relations
- Mr. Gregory Boss B.S., BS(Hons), J.D.Executive VP of Legal & Group General Counsel · born 1961
- Ms. Amy Van BurenChief People Officer · born 1975
- Dr. William Mezzanotte M.D., M.P.H.Chief Medical Officer, Executive VP and Head of Research & Development · born 1959
- Mr. Stephen MarlowExecutive VP & GM of CSL Plasma · born 1972
- Mr. Mark Hill B.A., M.B.A.Chief Digital Information Officer & Executive VP · born 1961
- Mr. Herve GisserotExecutive VP of Business Development & Enterprise Alliance Management · born 1965